European CHMP recommends approval of luspatercept for the treatment of adults with adults with transfusion-dependent anaemia associated with myelodysplastic syndromes (MDS) or beta-thalassaemia

Luspatercept is an erythroid maturation agent that inhibits Smad2/3 signalling, resulting in differentiation of erythroid precursors (normoblasts) and maturation of red blood cells. It has been shown to reduce the number of transfusions in patients with MDS or beta-thalassaemia.


European Medicines Agency